Patent applications related to cloud decreased by 35% per year on average in the pharmaceutical industry since 2020 

The global pharmaceutical industry experienced a 35% decline in annual average growth rate (AAGR) in the number of cloud-related patent applications between 2020 and 2022. The total number of cloud-related grants decreased by an AAGR of 24% during the same period, according to GlobalData's patent analytics database.

Notably, the number of cloud-related patent applications in the pharmaceutical industry was 209 since 2020, while 147 applications were granted.

Analysis of patent applications by company shows that AstraZeneca filed the most cloud patents within the pharmaceutical industry since 2020. The company filed six cloud-related patents since 2020.

It was followed by Vivia Biotech and Ipsen with three cloud patent applications each, and Endocanna Health and F. Hoffmann-La Roche with three applications each.

Analysis of patent grants by companies shows that Inspiring was granted four patents related to cloud within the pharmaceutical industry since 2020. It was followed by Nutravis (three grants), Nogra Two (two grants), and Copan Italia and Memorial Sloan Kettering Cancer Center with one grant each.

The largest share of cloud-related patent publications in the pharmaceutical industry since 2020 was held by China with 29%, followed by South Korea (17%) and Japan (14%).

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.  

GlobalData’s Patents Analytics tracks patent filings and grants from official patent offices around the world. Proprietary analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries